成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Metabolic Enzyme/Protease MAPK/ERK Pathway PI3K/Akt/mTOR Stem Cell/Wnt Apoptosis Protein Tyrosine Kinase/RTK
  3. Endogenous Metabolite MAP3K Akt Mitochondrial Metabolism ERK Apoptosis ROS Kinase
  4. Phosphocreatine

Phosphocreatine  (Synonyms: 磷酸胍酸; Creatine phosphate; Creatinephosphoric acid)

目錄號(hào): HY-D0885 純度: ≥95.0%
COA 產(chǎn)品使用指南 技術(shù)支持

Phosphocreatine (creatine phosphate) 是一種存在于脊椎動(dòng)物骨骼肌中的有機(jī)化合物。Phosphocreatine 增強(qiáng)抗氧化活性，激活 TAK1 通路以保護(hù)心臟。Phosphocreatine 通過(guò) Akt 介導(dǎo)的 Nrf2/HO-1 途徑使線粒體功能正常化并減少氧化應(yīng)激。Phosphocreatine 通過(guò) ERK 介導(dǎo)的 Nrf-2/HO-1 途徑抑制細(xì)胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的產(chǎn)生，從而保護(hù)腎臟。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Phosphocreatine Chemical Structure

Phosphocreatine Chemical Structure

CAS No. : 67-07-2

1.  客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶(hù)。

規(guī)格 價(jià)格 是否有貨 數(shù)量
100 mg ￥500
In-stock
200 mg   詢(xún)價(jià)  
500 mg   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Phosphocreatine:

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

查看 MAP3K 亞型特異性產(chǎn)品:

查看 Akt 亞型特異性產(chǎn)品:

查看 ERK 亞型特異性產(chǎn)品:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway.[1][2][3][4].

IC50 & Target

Human Endogenous Metabolite

 

體外研究
(In Vitro)

Phosphocreatine (0-1 mM, 24 h) 通過(guò)靶向 TAK1 揭示了抗氧化、抗凋亡和抗壞死性凋亡的作用，以保護(hù) H9c2 細(xì)胞免受 DOX (Doxorubicin) (HY-15142A) 誘導(dǎo)的心肌細(xì)胞損傷[2]。
Phosphocreatine (0-1 mM, 24 h) 通過(guò)增加抗氧化活性來(lái)緩解氧化應(yīng)激，隨后將 TAK1 的表達(dá)水平恢復(fù)到基線水平，并減少 DOX 誘導(dǎo)的心肌損傷中的細(xì)胞凋亡和程序性死亡[2]。
Phosphocreatine (5-20 mM, 24 h) 可減輕 MGO (Methylglyoxal) (HY-106634) 誘導(dǎo)的 PC12 細(xì)胞損傷和抑制 PC-12 細(xì)胞凋亡[3]。
Phosphocreatine (5-20 mM, 24 h) 可防止MGO (Methylglyoxal) 誘導(dǎo)損傷的PC-12 細(xì)胞線粒體膜通透性喪失[3]。
Phosphocreatine (5-20 mM, 2 h) 對(duì) PC-12 細(xì)胞的神經(jīng)保護(hù)作用依賴(lài)于通過(guò) Akt 介導(dǎo)的 Nrf2/HO- 1途徑使線粒體功能正常化和減少氧化應(yīng)激[3]。
Phosphocreatine (5-40 mM, 24 h) 在不同濃度下可能有助于保護(hù) NRK-52E 細(xì)胞免受 MGO 誘導(dǎo)的腎損傷[4]。
Phosphocreatine (10-40 mM, 4 h) 抑制腎臟氧化應(yīng)激代謝物[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 0, 5, 10, 20, 40 mM
Incubation Time: 24 h
Result: Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Apoptosis Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 5, 10, 20, 40 mM
Incubation Time: 2 h
Result: Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells..
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells..
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells..
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Western Blot Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 20, 40 mM
Incubation Time: 24 h
Result: Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
體內(nèi)研究
(In Vivo)

Phosphocreatine (200 mg/kg, i.p., 每隔一天一次, 7 周) 不僅減輕了氧化應(yīng)激和心肌細(xì)胞凋亡，而且挽救了 DOX 誘導(dǎo)的大鼠心臟毒性中的心肌壞死[2]。
Phosphocreatine (20-40 mg/kg, i.v., 每天, 6 周) 對(duì) SD (Sprague-Dawley) 大鼠的腎組織具有保護(hù)作用，可預(yù)防糖尿病腎病[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times [2].
Dosage: 200 mg/kg
Administration: i.p., once every other day, 7 weeks
Result: Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
Animal Model: Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks [4].
Dosage: 20, 40 mg/kg
Administration: i.p., daily, 6 weeks
Result: Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
Clinical Trial
分子量

211.11

Formula

C4H10N3O5P
CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱(chēng)

磷酸胍酸
結(jié)構(gòu)分類(lèi)
初始來(lái)源

skeletal muscles of vertebrates
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

H2O 中的溶解度 : 175 mg/mL (828.95 mM; 超聲助溶)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 4.7369 mL 23.6843 mL 47.3687 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
該產(chǎn)品水溶性佳，請(qǐng)具體參考實(shí)測(cè) 水 / PBS / Saline 中的溶解度數(shù)據(jù)。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
純度 & 產(chǎn)品資料

純度: ≥95.0%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 4.7369 mL 23.6843 mL 47.3687 mL 118.4217 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL 23.6843 mL
10 mM 0.4737 mL 2.3684 mL 4.7369 mL 11.8422 mL
15 mM 0.3158 mL 1.5790 mL 3.1579 mL 7.8948 mL
20 mM 0.2368 mL 1.1842 mL 2.3684 mL 5.9211 mL
25 mM 0.1895 mL 0.9474 mL 1.8947 mL 4.7369 mL
30 mM 0.1579 mL 0.7895 mL 1.5790 mL 3.9474 mL
40 mM 0.1184 mL 0.5921 mL 1.1842 mL 2.9605 mL
50 mM 0.0947 mL 0.4737 mL 0.9474 mL 2.3684 mL
60 mM 0.0789 mL 0.3947 mL 0.7895 mL 1.9737 mL
80 mM 0.0592 mL 0.2961 mL 0.5921 mL 1.4803 mL
100 mM 0.0474 mL 0.2368 mL 0.4737 mL 1.1842 mL

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱(chēng)：

  

* 需求量：

* 客戶(hù)姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱(chēng)：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱(chēng)：
Phosphocreatine
目錄號(hào)：
HY-D0885
需求量：